(NYSE: TAK) Takeda Pharmaceutical Co's forecast annual revenue growth rate of 0.27% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Takeda Pharmaceutical Co's revenue in 2025 is $29,988,259,705.On average, 1 Wall Street analysts forecast TAK's revenue for 2026 to be $47,491,048,545,874, with the lowest TAK revenue forecast at $47,491,048,545,874, and the highest TAK revenue forecast at $47,491,048,545,874. On average, 1 Wall Street analysts forecast TAK's revenue for 2027 to be $46,978,573,982,644, with the lowest TAK revenue forecast at $46,978,573,982,644, and the highest TAK revenue forecast at $46,978,573,982,644.
In 2028, TAK is forecast to generate $47,366,776,314,930 in revenue, with the lowest revenue forecast at $47,366,776,314,930 and the highest revenue forecast at $47,366,776,314,930.